Abstract
Since the first hand transplantation carried out in September 1998, there has been a great deal of discussion concerning the potential risks inducted by the immunosuppressive therapy for the patients transplanted, as they need lifelong immunosuppression. This discussion has been particularly emotional, as composite allograft transplantations (CAT) are not considered as life saving whereas immunosuppressive therapy can expose the recipients to serious side-effects and life-threatening complications. Transplantation is routinely indicated and accepted for non-life-threatening situations, such as dialysis-dependent renal failure and poorly controlled diabetes, because it allows a significant improvement in patient’s quality of life. Consequently, the above rationale might be applied to hand transplantation when functional recovery and improvement in quality of life are demonstrated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baumeister S, Kleist C, Dohler B et al (2004) Risks of allogeneic hand transplantation. Microsurgery 24:98–103
Frezza EE, Fung JJ, van Thiel DH (1999) Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 44:1172–1181
Jain AB, Yee LD, Nalesnik MA et al (1999) Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 66:1193–1200
Kinlen LJ, Sheil AG, Peto J, Doll R (1979) Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2:1461–1466
Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342:1514–1516
Penn I (1996) Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 2:52–59
Johnson C, Ahsan N, Gonwa T et al (2000) Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69:834–841
Miller J (1999) Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplant Proc 31:276–277
Pirsch JD, Miller J, Deierhoi MH et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977–983
Shapiro R, Jordan ML, Scantlebury VP et al (1995) A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 59(4):485–490
van Hooff JP, Christiaans MH, van Duijnhoven EM (2005) Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 79:1465–1469
Lanzetta M, Petruzzo P, Margreiter R et al (2005) The international registry on hand and composite tissue transplantation. Transplantation 79:1210–1214
Porter R, Crombie AL, Gardner PS, Uldall RP (1972) Incidence of ocular complications in patients undergoing renal transplantation. Br Med J 3:133–136
Mathew TH (1995) A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65:1450–1454
European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321–1325
Fung JJ, Alessiani M, Abu-Elmagd K et al (1991) Adverse effects associated with the use of FK 506. Transplant Proc 23:3105–3108
McCauley J, Takaya S, Fung J et al (1991) The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc 23:1444–1447
Porayko MK, Textor SC, Krom RA et al (1994) Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 69:105–111
Eidelman, BH, Abu-Elmagd K, Wilson J et al (1991) Neurologic complications of FK 506. Transplant Proc 23:3175–178
Sollinger, HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225–232
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Italia
About this chapter
Cite this chapter
Badet, L., Petruzzo, P., Lefrançois, N., Morelon, E., Martin, X., Dubernard, JM. (2007). Side-Effects and Potential Complications. In: Lanzetta, M., Dubernard, JM., Petruzzo, P. (eds) Hand Transplantation. Springer, Milano. https://doi.org/10.1007/978-88-470-0374-3_28
Download citation
DOI: https://doi.org/10.1007/978-88-470-0374-3_28
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0373-6
Online ISBN: 978-88-470-0374-3
eBook Packages: MedicineMedicine (R0)